Bridgeway Capital Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Bridgeway Capital Management’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-181,810	Closed	-$273K	–	1485
2023 Q1	$273K	Hold	181,810	–	–	0.01%	1044
2022 Q4	$182K	Buy	181,810 +50,000	+38%	+$67.4K	﹤0.01%	1107
2022 Q3	$237K	Buy	131,810 +33,410	+34%	+$96.9K	0.01%	1103
2022 Q2	$285K	Hold	98,400	–	–	0.01%	1007
2022 Q1	$272K	Buy	+98,400	New	+$310K	0.01%	1106

Bridgeway Capital Management's TCRR Position: Q2 2023 in Review

Bridgeway Capital Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 181,810 shares — an estimated $273K sold.

Bridgeway Capital Management first reported a position in TCRR in Q1 2022 and held it in 5 quarters. The position peaked at $285K in Q2 2022. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Bridgeway Capital Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Bridgeway Capital Management sold 181,810 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $273K.
Bridgeway Capital Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Bridgeway Capital Management's TCR2 Therapeutics Inc. Common Stock position peaked at $285K in Q2 2022.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Bridgeway Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.